Laparoscopy Quickly Abandoned in Early Cervical Cancer After LACC Results
(MedPage Today) -- SAN DIEGO -- Oncologic surgeons rapidly abandoned minimally invasive surgery (MIS) for early-stage cervical cancer in the wake of a startling 2018 study that warned of the dangers of the approach for this patient population... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 18, 2024 Category: Hematology Source Type: news
Immune Checkpoint Inhibitor-Chemo Combo Boosts OS in Advanced Endometrial Cancer
(MedPage Today) -- SAN DIEGO -- The addition of an immune checkpoint inhibitor (ICI) to chemotherapy up front improved overall survival (OS) in patients with advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 18, 2024 Category: Hematology Source Type: news
Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer
(MedPage Today) -- SAN DIEGO -- Treatment with raludotatug deruxtecan (R-DXd) led to an "exciting" response rate among patients with heavily pretreated, platinum-resistant advanced ovarian cancer, according to an early-phase trial.
In a subgroup... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 17, 2024 Category: Hematology Source Type: news
Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity'
(MedPage Today) -- Progression-free survival reasonably predicts overall survival in advanced prostate cancer and could bring new therapies to patients about 2 years faster if used as the primary endpoint in clinical studies. (University College... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 14, 2024 Category: Hematology Source Type: news
Rheumatologist Found Dead; How COVID Changed Lives; Olivia Munn's Breast Cancer
(MedPage Today) -- Note that some links may require registration or subscription.
A Connecticut rheumatologist was found dead after his arrest in a child sex abuse investigation. (WTNH)
Multiple class action lawsuits may join forces accusing... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 14, 2024 Category: Hematology Source Type: news
Novel CAR-T for Glioblastoma Induced 'Dramatic' Responses in Early Trial
(MedPage Today) -- A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study.
In the first-in-human trial, three patients with recurrent glioblastoma... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 14, 2024 Category: Hematology Source Type: news
Sickle Cell Pain Hospitalizations Rose After CDC's Opioid Recs
(MedPage Today) -- A downward trend in opioid prescribing practices for patients with sickle cell disease (SCD) followed the CDC's 2016 opioid guidelines for chronic pain, an analysis of claims data showed, but so did a steady increase in pain... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 11, 2024 Category: Hematology Source Type: news
First-Line Nivolumab Plus Chemo Approved for Bladder Cancer
(MedPage Today) -- The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma, the agency announced... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
First-Line Immunotherapy Alone Sufficient for Older NSCLC Patients, Study Suggests
(MedPage Today) -- Adding an immune checkpoint inhibitor (ICI) to chemotherapy for older patients with previously untreated advanced non-small cell lung cancer (NSCLC) provided no survival advantage compared with ICI therapy alone, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu
(MedPage Today) -- An interim analysis of the DREAMM-8 trial showed belantamab mafodotin (Blenrep) improved progression-free survival when combined with pomalidomide (Pomalyst) and dexamethasone as second-line treatment for patients with relapsed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients
(MedPage Today) -- Older patients with classical Hodgkin lymphoma unsuitable for conventional chemotherapy had high rates of durable responses with two brentuximab vedotin (BV; Adcetris) regimens, one that omitted chemotherapy, a small prospective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 7, 2024 Category: Hematology Source Type: news
FDA OKs First Interchangeable Biosimilars for Denosumab
(MedPage Today) -- The FDA approved injectable Jubbonti and Wyost as the first interchangeable biosimilars to denosumab (Prolia, Xgeva), and for all the same indications, including the prevention of fractures in at-risk adults and skeletal-related... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 6, 2024 Category: Hematology Source Type: news
All-Oral AML Regimen Shows Promise for Older, Unfit Patients
(MedPage Today) -- An all-oral combination of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) was active and safe in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive chemotherapy, results of a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news
Novel Therapy Promising for Radiation-Induced Oral Mucositis
(MedPage Today) -- The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck who underwent radiation therapy, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news
Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- Gene-guided treatment selection for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) failed to improve disease control versus random treatment selection in a small preliminary clinical trial.
Personalized treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 4, 2024 Category: Hematology Source Type: news